clinical trial · NCT05075538
COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2
Jules Bordet Institute·phase4·terminated·n = 152
CancerSpikevaxComirnatySpikevax bivalent Original/Omicron BA.1Spikevax bivalent Original/Omicron BA.4-5Comirnaty Original/Omicron BA.1Comirnaty Original/Omicron BA.4-5Comirnaty Omicron XBB.1.5Spikevax Omicron XBB.1.5
brief summary
This trial aims to measure the humoral and adaptive immune response in patients with cancer diagnosis undergoing mRNA vaccination against SARS-CoV-2 and assess its efficacy in preventing COVID-19.
started
Dec 1, 2021
primary completion
Jan 8, 2024
completion
Jan 8, 2024
last updated
Jan 17, 2024
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol